Meltem Baykara
- Dermatology top 10%
-
- Cancer Diagnosis and Treatment 8
- Inflammatory Biomarkers in Disease Prognosis 4
- HER2/EGFR in Cancer Research 3
-
- Head and Neck Cancer Studies 6
-
- Gastric Cancer Management and Outcomes 3
-
- Cancer, Lipids, and Metabolism 4
-
- Ocular Oncology and Treatments 3
-
- Head and Neck Surgical Oncology 3
- Co-authors
- Mustafa BeneklıUğur ÇoşkunUmut DemırcıSüleyman BuyukberberAhmet ÖzetSíbel SüzenNilufer YükselKaplan Ma
- Journals
- Journal of Clinical Oncology (3 papers)SHILAP Revista de lepidopterología (4 papers)Scientific Reports (1 paper)
- Partner nations
- TürkiyeUnited StatesColombia
In The Last Decade
Meltem Baykara
40 papers receiving 341 citations
Peers
Comparison fields: 5 of 64
- Dermatology 53
- Oncology 153
- Otorhinolaryngology 21
- Pulmonary and Respiratory Medicine 118
- Cancer Research 41
Countries citing papers authored by Meltem Baykara
This map shows the geographic impact of Meltem Baykara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meltem Baykara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meltem Baykara more than expected).
Fields of papers citing papers by Meltem Baykara
This network shows the impact of papers produced by Meltem Baykara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meltem Baykara. The network helps show where Meltem Baykara may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Meltem Baykara, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2023 | 1 | |
| 3 | 2023 | 0 | |
| 4 | 2022 | 17 | |
| 5 | 2022 | 0 | |
| 6 | Prognostic role of pre-operative serum ferritin level in stage 2 colon cancer | 2021 | 4 |
| 7 | 2016 | 5 | |
| 8 | 2014 | 8 | |
| 9 | 2014 | 3 | |
| 10 | 2014 | 19 | |
| 11 | 2013 | 10 | |
| 12 | 2013 | 10 | |
| 13 | 2012 | 11 | |
| 14 | 2011 | 48 | |
| 15 | 2011 | 10 | |
| 16 | 2011 | 4 | |
| 17 | 2010 | 12 | |
| 18 | 2010 | 30 | |
| 19 | 2009 | 10 | |
| 20 | 2004 | 18 |
About Meltem Baykara
Meltem Baykara is a scholar working on Otorhinolaryngology, Oncology and Cancer Research, having authored 48 papers that have together received 349 indexed citations. Recurring topics across this work include Cancer Diagnosis and Treatment (8 papers), Head and Neck Cancer Studies (6 papers), Cancer, Lipids, and Metabolism (4 papers), Inflammatory Biomarkers in Disease Prognosis (4 papers), HER2/EGFR in Cancer Research (3 papers), Gastric Cancer Management and Outcomes (3 papers), Ocular Oncology and Treatments (3 papers) and Head and Neck Surgical Oncology (3 papers). The work is most often cited by research in Dermatology (53 citations), Oncology (153 citations) and Otorhinolaryngology (21 citations). Meltem Baykara has collaborated with scholars based in Türkiye, United States and Colombia. Frequent co-authors include Mustafa Beneklı, Uğur Çoşkun, Umut Demırcı, Süleyman Buyukberber, Ahmet Özet, Síbel Süzen, Nilufer Yüksel, Kaplan Ma, Nurullah Zengin and Aytuğ Üner. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.